RDY | tickerfilter.com

Fundamental analysis

47%

Profitability 61%

Dept financing 9%

Liquidity 43%

Performance 43%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

-0.70%

1 Month

2.22%

3 Months

0.63%

6 Months

-0.42%

1 Year

10.53%

2 Year

-81.16%

Key data

Stock price

$14.28

P/E Ratio

0.00

DAY RANGE

$14.24 - $14.49

EPS

$1.21

52 WEEK RANGE

$12.26 - $16.17

52 WEEK CHANGE

$9.93

MARKET CAP

13.933 B

YIELD

0.57%

SHARES OUTSTANDING

166.923 M

DIVIDEND

$0.0933

EX-DIVIDEND DATE

07-10-2025

NEXT EARNINGS DATE

N/A

BETA

0.26

PUBLIC FLOAT

AVERAGE 10 VOLUME

$1,774,642

AVERAGE 30 VOLUME

$1,945,878

Company detail

CEO: Erez Israeli
Region: US
Website: drreddys.com
Employees: 24,800
IPO year: 2001

Issue type: American Depository Receipt (ADR’s)
Market: NYSE
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Dr. Reddy's Laboratories Limited operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients, Proprietary Products, and Others segments. Its therapeutic categories include gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology.

RDY - DR REDDYS LABORATORIES LTD